The global HIV drugs market size reached US$ 31.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 43.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.7% during 2023-2032. The market is experiencing steady growth driven by the increasing awareness and prevention efforts, the growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.
Technological Advancements: Technological advancements have led to the development of more potent and tolerable antiretroviral drugs. Improved drug delivery mechanisms, such as long-acting injectables, have increased treatment adherence. Besides, telemedicine and mobile health apps are enhancing patient management and monitoring.
Industry Applications: The HIV drugs market serves patients living with HIV/AIDS worldwide. It also has applications in preventive treatments, including pre-exposure prophylaxis (PrEP) for high-risk populations. Moreover, the industry collaborates with governments, NGOs, and healthcare providers to ensure access to medications and care.
Geographical Trends: High prevalence regions like sub-Saharan Africa and parts of Asia drive significant demand. North America and Europe also have substantial markets due to access to advanced treatments. Besides, emerging markets in Latin America and Asia-Pacific are witnessing growth.
Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. These strategies aim to enhance product portfolios, meet specific industry needs, and address the challenges of an evolving market.
Challenges and Opportunities: Challenges include the need for continuous treatment, drug resistance, and the high cost of some medications. Opportunities lie in developing more affordable and accessible drugs, expanding prevention efforts, and research into potential cures.
Future Outlook: The future of the HIV drugs market holds promise, with ongoing research aiming for a functional cure and long-acting therapies. Increased access to medications and prevention methods remains a global health priority. Moreover, market growth is expected to continue, driven by technological advancements and expanded treatment programs.
The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.
Advancements in treatments
Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences.
Increasing awareness among patients
Enhanced awareness and diagnostic rates are pivotal in driving the market for HIV drugs. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.
Rising focus on combination therapies
Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. The growing preference for combination therapies among healthcare providers and patients is a key factor driving the market for HIV drugs.
Multi-Class Combination Products
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
Fusion Inhibitors and Others
Nucleoside reverse transcriptase inhibitors accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors - CCR5 co-receptor antagonist, fusion inhibitors and others. According to the report, nucleoside reverse transcriptase inhibitors represented the largest segment.
NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.
Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.
Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.
Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.
NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.
CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.
Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).
Retail Pharmacies
Online Pharmacies
Others
Hospital pharmacies holds the largest share in the industry
A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies and others. According to the report, hospital pharmacies accounted for the largest market share.
Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.
Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.
Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.
Europe
Asia Pacific
Middle East and Africa
Latin America
North America leads the market, accounting for the largest HIV drugs market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.
Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.
The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.
Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.
The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.
Merck & Co., Inc.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Gilead Sciences, Inc.
Johnson & Johnson
Cipla Limited
Daiichi Sankyo
Emcure Pharmaceuticals
Hetero Drugs
Mylan N.V
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
June 2022: Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for younger children. This innovative treatment has been approved by the South African Health Products Regulatory Authority (SAHPRA) and is specifically designed for infants and young children living with HIV.
In 2021: Johnson & Johnson has also been actively involved in the development of HIV drugs. In 2021, the company received FDA approval for its new antiretroviral drug, Rekambys, which is a long-acting injectable treatment option for HIV-1 infection in certain patients.
2. What is the expected growth rate of the global HIV drugs market during 2024-2032?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
HIV Drugs Market Analysis:
Market Growth and Size: The global HIV drugs market has witnessed steady growth in recent years. It is expected to continue growing due to the increasing prevalence of HIV/AIDS and the expansion of treatment programs.Technological Advancements: Technological advancements have led to the development of more potent and tolerable antiretroviral drugs. Improved drug delivery mechanisms, such as long-acting injectables, have increased treatment adherence. Besides, telemedicine and mobile health apps are enhancing patient management and monitoring.
Industry Applications: The HIV drugs market serves patients living with HIV/AIDS worldwide. It also has applications in preventive treatments, including pre-exposure prophylaxis (PrEP) for high-risk populations. Moreover, the industry collaborates with governments, NGOs, and healthcare providers to ensure access to medications and care.
Geographical Trends: High prevalence regions like sub-Saharan Africa and parts of Asia drive significant demand. North America and Europe also have substantial markets due to access to advanced treatments. Besides, emerging markets in Latin America and Asia-Pacific are witnessing growth.
Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. These strategies aim to enhance product portfolios, meet specific industry needs, and address the challenges of an evolving market.
Challenges and Opportunities: Challenges include the need for continuous treatment, drug resistance, and the high cost of some medications. Opportunities lie in developing more affordable and accessible drugs, expanding prevention efforts, and research into potential cures.
Future Outlook: The future of the HIV drugs market holds promise, with ongoing research aiming for a functional cure and long-acting therapies. Increased access to medications and prevention methods remains a global health priority. Moreover, market growth is expected to continue, driven by technological advancements and expanded treatment programs.
HIV Drugs Market Trends:
The growing prevalence of HIV/AIDSThe global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.
Advancements in treatments
Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences.
Increasing awareness among patients
Enhanced awareness and diagnostic rates are pivotal in driving the market for HIV drugs. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.
Rising focus on combination therapies
Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. The growing preference for combination therapies among healthcare providers and patients is a key factor driving the market for HIV drugs.
HIV Drugs Industry Segmentation:
The report provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.Breakup by Drug Class:
Nucleoside Reverse Transcriptase InhibitorsMulti-Class Combination Products
Protease Inhibitors
HIV Integrase Strand Transfer Inhibitors
Non-Nucleoside Reverse Transcriptase Inhibitors
Entry Inhibitors - CCR5 Co-Receptor Antagonist
Fusion Inhibitors and Others
Nucleoside reverse transcriptase inhibitors accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the drug class. This includes nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors - CCR5 co-receptor antagonist, fusion inhibitors and others. According to the report, nucleoside reverse transcriptase inhibitors represented the largest segment.
NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.
Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.
Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.
Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.
NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.
CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.
Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).
Breakup by Distribution Channel:
Hospital PharmaciesRetail Pharmacies
Online Pharmacies
Others
Hospital pharmacies holds the largest share in the industry
A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies and others. According to the report, hospital pharmacies accounted for the largest market share.
Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.
Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.
Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.
Breakup by Region:
North AmericaEurope
Asia Pacific
Middle East and Africa
Latin America
North America leads the market, accounting for the largest HIV drugs market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.
Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.
The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.
Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.
The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.
Leading Key Players in the HIV Drugs Industry:
Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
Boehringer Ingelheim International GmbHMerck & Co., Inc.
ViiV Healthcare
AbbVie
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Gilead Sciences, Inc.
Johnson & Johnson
Cipla Limited
Daiichi Sankyo
Emcure Pharmaceuticals
Hetero Drugs
Mylan N.V
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Latest News:
2021: Merc received approval from the U.S. Food and Drug Administration (FDA) for its new antiretroviral drug, Isentress HD, which offers improved dosing convenience for patients. The introduction of ISENTRESS HD reflects Merck's commitment to innovation in HIV therapy, offering a broader range of treatment options to fit the individual needs and lifestyles of people living with HIV. The price of ISENTRESS HD is set to be the same as the twice-daily ISENTRESS, and it was anticipated to be available in pharmacies approximately four weeks following the approval announcement.June 2022: Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for younger children. This innovative treatment has been approved by the South African Health Products Regulatory Authority (SAHPRA) and is specifically designed for infants and young children living with HIV.
In 2021: Johnson & Johnson has also been actively involved in the development of HIV drugs. In 2021, the company received FDA approval for its new antiretroviral drug, Rekambys, which is a long-acting injectable treatment option for HIV-1 infection in certain patients.
Key Questions Answered in This Report
1. What was the size of the global HIV drugs market in 2023?2. What is the expected growth rate of the global HIV drugs market during 2024-2032?
3. What has been the impact of COVID-19 on the global HIV drugs market?
4. What are the key factors driving the global HIV drugs market?
5. What is the breakup of the global HIV drugs market based on the drug class?
6. What is the breakup of the global HIV drugs market based on the distribution channel?
7. What are the key regions in the global HIV drugs market?
8. Who are the key players/companies in the global HIV drugs market?
Table of Contents
1 Preface3 Executive Summary
2 Scope and Methodology
4 Introduction
5 Global HIV Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 HIV Drugs Manufacturing Process
10 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Boehringer Ingelheim International GmbH
- Merck & Co. Inc
- ViiV Healthcare
- AbbVie
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Gilead Sciences Inc
- Johnson & Johnson
- Cipla Limited
- Daiichi Sankyo
- Emcure Pharmaceuticals
- Hetero Drugs
- Mylan N.V
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | July 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 31.7 Billion |
| Forecasted Market Value ( USD | $ 43.9 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
